These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 21288720)

  • 1. Discordance in early breast cancer for tumour grade, estrogen receptor, progesteron receptors and human epidermal receptor-2 status between core needle biopsy and surgical excisional primary tumour.
    Lorgis V; Algros MP; Villanueva C; Chaigneau L; Thierry-Vuillemin A; Nguyen T; Demarchi M; Bazan F; Sautiere JL; Maisonnette-Lescot Y; Ringenbach F; Bontemps P; Pivot X
    Breast; 2011 Jun; 20(3):284-7. PubMed ID: 21288720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Accuracy of estrogen receptor, progesterone receptor, and HER2 status between core needle and open excision biopsy in breast cancer: a meta-analysis.
    Chen X; Yuan Y; Gu Z; Shen K
    Breast Cancer Res Treat; 2012 Aug; 134(3):957-67. PubMed ID: 22370627
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of host and histopathological factors on the discrepancies in estrogen receptor, and progesterone receptor, and HER2 status between core needle biopsy and surgically excised tumors.
    Nakamura R; Yamamoto N; Shiina N; Miyaki T; Ikebe D; Itami M; Shida T; Miyazaki M
    Breast; 2016 Apr; 26():141-7. PubMed ID: 26732051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reliability of prognostic factors in breast carcinoma determined by core needle biopsy.
    Usami S; Moriya T; Amari M; Suzuki A; Ishida T; Sasano H; Ohuchi N
    Jpn J Clin Oncol; 2007 Apr; 37(4):250-5. PubMed ID: 17485439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group.
    Kyndi M; Sørensen FB; Knudsen H; Overgaard M; Nielsen HM; Overgaard J;
    J Clin Oncol; 2008 Mar; 26(9):1419-26. PubMed ID: 18285604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The accuracy of preoperative core biopsy in determining histologic grade, hormone receptors, and human epidermal growth factor receptor 2 status in invasive breast cancer.
    Park SY; Kim KS; Lee TG; Park SS; Kim SM; Han W; Noh DY; Kim SW
    Am J Surg; 2009 Feb; 197(2):266-9. PubMed ID: 18614146
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surgical specimen can be replaced by core samples in assessment of ER, PR and HER-2 for invasive breast cancer.
    Sutela A; Vanninen R; Sudah M; Berg M; Kiviniemi V; Rummukainen J; Kataja V; Kärjä V
    Acta Oncol; 2008; 47(1):38-46. PubMed ID: 17851859
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Results with accelerated partial breast irradiation in terms of estrogen receptor, progesterone receptor, and human growth factor receptor 2 status.
    Wilder RB; Curcio LD; Khanijou RK; Eisner ME; Kakkis JL; Chittenden L; Agustin J; Lizarde J; Mesa AV; Macedo JC; Ravera J; Tokita KM
    Int J Radiat Oncol Biol Phys; 2010 Nov; 78(3):799-803. PubMed ID: 20869583
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Breast hormonal receptors test should be repeated on excisional biopsy after negative core needle biopsy.
    Khoury T; Zakharia Y; Tan W; Kulkarni S; Liu W; Zhang S; Wilding GE; Edge S
    Breast J; 2011; 17(2):180-6. PubMed ID: 21306471
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of core needle biopsy (CNB) and surgical specimens for accurate preoperative evaluation of ER, PgR and HER2 status of breast cancer patients.
    Tamaki K; Sasano H; Ishida T; Miyashita M; Takeda M; Amari M; Tamaki N; Ohuchi N
    Cancer Sci; 2010 Sep; 101(9):2074-9. PubMed ID: 20557310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preoperative profiling of symptomatic breast cancer by diagnostic core biopsy.
    Cahill RA; Walsh D; Landers RJ; Watson RG
    Ann Surg Oncol; 2006 Jan; 13(1):45-51. PubMed ID: 16378157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reliance on hormone receptor assays of surgical specimens may compromise outcome in patients with breast cancer.
    Mann GB; Fahey VD; Feleppa F; Buchanan MR
    J Clin Oncol; 2005 Aug; 23(22):5148-54. PubMed ID: 16051956
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant chemotherapy of breast cancer: tumor markers as predictors of pathologic response, recurrence, and survival.
    Precht LM; Lowe KA; Atwood M; Beatty JD
    Breast J; 2010; 16(4):362-8. PubMed ID: 20443786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Comparison of touch imprint cytology of core needle biopsy and section histopathology in breast cancer diagnosis].
    Zhang ZH; Zhao LL; Guo HQ; Zheng S; Zhang BL; Xu XZ; Pan QJ; Zhang BN
    Zhonghua Zhong Liu Za Zhi; 2010 Dec; 32(12):921-6. PubMed ID: 21223801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concordance between core needle biopsy and surgical specimen for oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 status in breast cancer.
    Asogan AB; Hong GS; Arni Prabhakaran SK
    Singapore Med J; 2017 Mar; 58(3):145-149. PubMed ID: 27029805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discordance between core needle biopsy (CNB) and excisional biopsy (EB) for estrogen receptor (ER), progesterone receptor (PgR) and HER2 status in early breast cancer (EBC).
    Arnedos M; Nerurkar A; Osin P; A'Hern R; Smith IE; Dowsett M
    Ann Oncol; 2009 Dec; 20(12):1948-52. PubMed ID: 19570962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of immunohistochemical staining for oestrogen receptor, progesterone receptor and HER-2 in breast core biopsies and subsequent excisions.
    Wood B; Junckerstorff R; Sterrett G; Frost F; Harvey J; Robbins P
    Pathology; 2007 Aug; 39(4):391-5. PubMed ID: 17676479
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human epidermal growth factor receptor 2 status correlates with lymph node involvement in patients with estrogen receptor (ER) negative, but with grade in those with ER-positive early-stage breast cancer suitable for cytotoxic chemotherapy.
    Bartlett JM; Ellis IO; Dowsett M; Mallon EA; Cameron DA; Johnston S; Hall E; A'Hern R; Peckitt C; Bliss JM; Johnson L; Barrett-Lee P; Ellis P
    J Clin Oncol; 2007 Oct; 25(28):4423-30. PubMed ID: 17906205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of neoadjuvant chemotherapy on Ki67 labelling index, c-erbB-2 expression and steroid hormone receptor status in human breast tumours.
    Bottini A; Berruti A; Bersiga A; Brunelli A; Brizzi MP; Marco BD; Cirillo F; Bolsi G; Bertoli G; Alquati P; Dogliotti L
    Anticancer Res; 1996; 16(5B):3105-10. PubMed ID: 8920776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tissue confirmation of disease recurrence in breast cancer patients: pooled analysis of multi-centre, multi-disciplinary prospective studies.
    Amir E; Clemons M; Purdie CA; Miller N; Quinlan P; Geddie W; Coleman RE; Freedman OC; Jordan LB; Thompson AM
    Cancer Treat Rev; 2012 Oct; 38(6):708-14. PubMed ID: 22178456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.